CB Company

On the basis of results from qualitative interviews and an online survey online survey, the prejudices and practical problems faced by people practical problems people who use cannabis for medical reasons still face people who use cannabis for medical reasons still have to deal with, even in times of (theoretically) legal supply. There is a considerable number of people who, despite manifest symptoms that can be treated with cannabis symptoms that can be treated well with cannabis, or who, after

or who, after many years of bad experiences with medicine and law enforcement do not even try to get a legal supply. The inadequate implementation of the Cannabis as Medicine Act not only ensures that such not only ensures that such people continue to be at risk of prosecution, but also that prosecution, but also ensures that there is still a great deal of reluctance in the medical world.

Language: German

Speaker

• Dr. Bernd Werse (Speaker), Goethe-Universität, Centre for Drug Research, Social scientist (senior staff member)

Language: English

Speaker

• Dr. Pavel Kubu MD (Speaker), Chain Pharmaceuticals GmbH, Chief Information Officer

Building medical cannabis companies and brands that resonate with patients can be extremely difficult in highly regulated markets. Acquiring new patients can be even more challenging, given the stringent restrictions on advertising and marketing. This situation presents a unique set of challenges for medical cannabis companies across Europe. In this masterclass, participants will hear from some of the most successful European medical cannabis companies about how they have managed to connect with patients and acquire them. Attendees will gain actionable advice and insights.

Language: English

Speakers

• Georgia Glick (Moderator), Tocar Strategic Advisors/ Hanway, Partner
• Dr. Julian Wichmann (Speaker), Bloomwell Group, Co-Founder
• Dave Barton (Speaker), thermidor, Co-Founder, Creative Director
• Calvin Rasode (Speaker), Brains Bioceutical Corp, Vice President, Marketing

There are over 200 medical cannabis products available in Germany, yet only 2 of them have market authorisation, why is that? Today's panel will be discussing why such few companies have pursued drug development and market authorisation. What role will approved finished drugs play in the future and what is the impact of legalisation of recreational cannabis? Will legislation affect the type of products available to patients? Our expert panel will provide their insights on the future of the German medical market.

Language: English

Speakers

• Bijan Christoph Hezarkhani (Moderator), BijanChristoph.com, Business Development
• Ana Serrato (Speaker), Avextra Pharma, Head Drug Development
• Bertan Türemis (Speaker), Fette Pharma GmbH, Medical Science Liaison
• Maximilian Schmitt (Speaker), Cannaflos - Gesellschaft für medizinisches Cannabis GmbH, Co-Founder & CEO

The cannabis plant uses a wide palette of terpenes and minor cannabinoids to produce its array of effects. But for consumers and producers of whole plant products, they are plagued by the inconsistencies inherent to a botanical product. The winning cannabinoid products of the future will contain unique formulations of terpenes and cannabinoids for directed consistent effects. Lex Pelger will highlight what's known about some of the most important minor cannabinoids and terpenes and the potential combinations that may become popular.

Language: English

Speaker

• Lex Pelger (Speaker), White Whale Creations, Founder

In the landscape of CBD, a significant hurdle emerges - only a mere 6% of a dose is accessible for the body's absorption, as indicated by a report from the World Health Organization (WHO). This fact beckons a compelling question: How can we unlock enhanced CBD absorption and unleash its full potential? Dr. Sung-Min Pyo, expert in pharmaceutical formulation and frequent guest lecturer at globally renown universities, will lead an illuminating session that peers into the depths of this challenge. Discover the transformative power of advanced drug delivery technologies capable of elevating the body's uptake of CBD and other cannabinoids like THC by an astounding 8-fold.

Language: English

Speaker

• Dr. Sung-Min Pyo (Speaker), Pyo Labs Ltd., CEO

A comprehensive understanding of the current position, and where we go from here.

The regulation of cannabis for adult use in Europe presents a myriad of challenges for member states. While some are adopting an incremental approach to address the issue, the need for a cohesive and comprehensive regulatory framework at the European level becomes increasingly apparent. Harmonising cannabis regulations across Europe would facilitate consistency, improve public health and safety standards, promote fair market competition, and ultimately pave the way for a more effective and sustainable cannabis industry. Join us as we explore the crucial role of European-level regulation in shaping the future of cannabis policy and its impact on society.

Language: English

Speakers

• Niall Neligan (Moderator), The Cannabis Summit, Barrister-at-Law | CEO
• Kai-Friedrich Niermann (Speaker), KFN+ Law Office, Lawyer and Founder
• Frantisek Svejda (Speaker), HEMP FACTORY s.r.o., CEO
• Jiří Velechovský (Speaker), SensiQure s.r.o., Co-Founder & Head of Cultivation
• Sean Carney (Speaker), Herbology Ventures s.r.o., Executive Director

From ADAC e.V. to Cannabis Club e.V. - What legal requirements should be created today in Pillar I in order to successfully implement social clubs? What do prospective cannabis club associations need to know and observe? And is an exit or transition to a model project possible later, when Pillar II comes? An analysis of the law on associations, companies and the upcoming law. Let's regulate!

Language: German

Speakers

• Lito Michael Schulte (Moderator), Lito Law Academy GmbH, Managing Director & Lawyer
• Emanuel Kotzian (Speaker), Chillisimo e.V., Chairman
• Nikita Cretu (Speaker), Lumino, Co-founder & COO
• Luc Richner (Speaker), Cannavigia - Vigia AG, Co-founder & CEO

CBD - A Question of Demarcation?

CBD: Popular Among Consumers, a Regulatory Challenge. After the CBD hype of recent years, companies are facing increasing challenges in the market. The marketability of products is dependent on category-appropriate marketing. The accusation of misuse and the controlled substances status of industrial hemp still play a role. What does the future hold for industrial hemp products post-legalization? What role do pharmaceutical laws, Novel Food, Cosing, and TPD play now, and what changes will occur with the Cannabis Act?

Language: English

Speakers

• Lisa Haag (Moderator), MJ Universe GmbH, CEO
• Sven Kalies (Speaker), BvCW e. V., Bord member
• Lukas Rausse (Speaker), Arvaloo GmbH, Co-Founder & CEO
• Sébastien Ludovic Béguerie (Speaker), Canèbe S.R.O., Alpha-Cat, Kanavape, Golden Buds, Ing. MSc Plant Sciences, CEO, Founder and Creator

In order to meet the regulatory requirements (Novel Food application) and to open up the outstanding prospects of the CBD market (food and nutritional supplements) for our members and partners, EIHA is conducting a Novel Food application for CBD isolates and hemp extracts. The subsidiary responsible for this, EIHA projects GmbH, is investing a total of approx. 3.5 million EUR in the necessary toxicology studies on CBD and THC. The complete submission of all study data is expected in mid-2024.

Language: German

Speaker

• Daniel Kruse (Speaker), EIHA, President